Phenomenex and ChromaDex® Announces Collaboration Agreement
News Oct 03, 2012
Phenomenex Inc. and ChromaDex® Corporation have announced a collaboration agreement that will provide solutions to customers with a combination of reference standards, scientifically valid methods and application support.
The collaboration combines Phenomenex’s strengths in analytical HPLC (high-performance liquid chromatography) with ChromaDex’s extensive line of reference standards, which are used for quality control in dietary supplement manufacturing.
The first three new solutions will be presented as scientific posters at the AOAC (Association of Analytical Communities) annual meeting in Las Vegas next week and will be available as technical notes, the first of which can be viewed at www.phenomenex.com/cdpr.
The FDA has increased its scrutiny of the supplement industry in recent years, precipitating a need for faster, more advanced quality control methods.
“The ability to provide a complete package of reference standards and scientifically valid methods strengthens our leadership position and provides a ‘one stop shop’ for our customers,” said Frank Jaksch, CEO and founder of ChromaDex.
Jaksch continued, “The collaboration will deliver tools to help customers meet FDA guidance on cGMP (current good manufacturing practices) for dietary supplements.”
Phenomenex maintains a full-service analytical support laboratory, staffed with application scientists who specialize in method development and customized solutions.
This team will optimize methods for ChromaDex reference standards, based on the most advanced chromatography technology.
This includes working with a variety of sample matrices and will in many cases include the use of Phenomenex’s core-shell particle technology and Kinetex® columns.
“This collaboration is consistent with our strategy of providing the most complete solutions to the customers we serve,” explains Sky Countryman, manager of PhenoLogix and applied technology for Phenomenex. “We look forward to expanding our involvement with the growing dietary supplement market.”
Salmonella Cases No Longer Declining in the EUNews
The declining trend of salmonellosis cases in the EU has levelled off according to the annual report on zoonotic diseases. Cases of Salmonella Enteritidis acquired in the EU have increased in humans by 3% since 2014 and in laying hens, the prevalence increased from 0.7% to 1.21% over the same period.
New Rapid Test for Valley Fever Should Help Reduce Diagnosis DelaysNews
November saw a spike if cases of Valley fever. Fortunately, the recent—and timely—approval of a new rapid assay test for Valley fever should reduce delays in diagnosing the respiratory fungal infections—a frequent problem in treating the disease, which is caused by spores endemic to soils in the U.S. Southwest.READ MORE
Bringing ‘Avatar’-Like Glowing Plants to the Real WorldNews
The 2009 film “Avatar” created a lush imaginary world, illuminated by magical, glowing plants. Now researchers are starting to bring this spellbinding vision to life to help reduce our dependence on artificial lighting.READ MORE